Clinical Trial

A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a randomized, double-blind, placebo-controlled Phase III clinical study designed to demonstrate that TQB3473 tablets significantly improve the sustained response rate compared to placebo in adult patients with chronic ITP who have previously received standard corticosteroid therapy and have failed or relapsed after at least one standard ITP treatment. The study consists of a treatment period and a safety follow-up period.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-24; most recent amendment 2025-05-18.
Status change: Not Yet Recruiting → Recruiting 2025-05-18
Trial Details
NCT Number NCT06900920
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Primary Immune Thrombocytopenia
Enrollment 199 participants
Start Date 2025-04-30
Primary Completion 2027-03 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-05-20